Zomato founder's Temple buys London longevity firm Longévous ahead of hardware launch
What's the deal? Temple, the health-tech startup founded by Zomato's Deepinder Goyal, has acquired London-based longevity medical practice LongévousDealroom has a profile for this one. Try Dealroom →. The move brings clinical depth to a company preparing to launch its first consumer wearable.
The hire: As part of the deal, Longévous founders Dr Robert Mohr and Dr Avi Roy join Temple as chief medical officer and head of science, respectively. Both roles anchor the startup's push from research into a commercial product.
Why now? Temple is moving out of its R&D phase toward a commercial launch. The device will track physiological signals such as cerebral blood flow and oxygen levels, and the acquisition is aimed at strengthening its clinical research.
What's the endgame? Temple wants to close the gap between consumer wearable data and clinical validation. The new medical hires are meant to lend scientific credibility to its upcoming health device.
The money: Temple is valued at $375 million and has raised $54 million in seed funding from Peak XV Partners and Steadview CapitalDealroom has a profile for this one. Try Dealroom →. To scale production, it has signed manufacturing partnerships with Zetwerk and Ethereal Machines, with a few thousand units in preparation.
What could go wrong? Scaling hardware is costly and difficult. Some experts have also questioned Temple's "Entropy" health metric, leaving the company to prove the clinical value of its technology.
The signal: Consumer health wearables increasingly live or die on clinical credibility, not just data collection. By buying a medical practice rather than building the expertise in-house, Temple is betting that validated science is the fastest route to market.
Read more: whalesbook.com
Image credit: Generated with Gemini
